Morningstar
•
Oct 28, 2026
Boston Scientific Corporation: Boston Scientific Faces Heightened Competition and a Lull in Its PFA New Products in 2027
Summary
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Daily – Vickers Top Buyers & Sellers for 10/30/2026
Oct 30, 2026
•
TFC, IBKR, ENVA, HBAN, DINO, TRV, XYL, PNFP, DHR
Analyst Report: Thermo Fisher Scientific Inc
Oct 30, 2026
•
TMO
Market Digest: AMZN, TT, KLAC, LLY, LMT, MSFT, PSA, TMO, MA, AGNC, HLT, STRL
Oct 30, 2026
•
KLAC, TT, MSFT, HLT, LMT, MA, AGNC, TMO, LLY, STRL, AMZN, PSA
Analyst Report: Bristol-Myers Squibb Company
Oct 30, 2026
•
BMY
Analyst Report: Stryker Corporation
Oct 30, 2026
•
SYK
Analyst Profile
Debbie S. Wang
Senior Equity Analyst
Debbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.
